Farouk Abdelkader Mohamed, Abd-Elhamid Mehany Elwan Shaaban, Shawkat Abdelhalim Ahmed
Ophthalmology Department, Faculty of Medicine, Minia University, El-Minia, Egypt.
J Ophthalmol. 2020 Oct 7;2020:6938627. doi: 10.1155/2020/6938627. eCollection 2020.
To evaluate the efficacy and safety of the simultaneous use of short-term perfluoro-n-octane (PFO) with perfluoropropane (C3F8) gas to achieve retinal reattachment in eyes with rhegmatogenous retinal detachment (RRD) with proliferative vitreoretinopathy (PVR) grade C and multiple retinal breaks including inferior breaks.
This is a prospective interventional case series study. . The study was a prospective noncomparative interventional study. It included 30 eyes of 30 patients who had RRD with PVR grade C and multiple retinal breaks including inferior tears attending the vitreoretinal unit of Minia University Hospital, Egypt. The mean age was 50.2 ± 10.63 years; 18 patients were females and 12 were males. Combined phacoemulsification and 23 G pars plana vitrectomy (PPV) with double retinal tamponade by C3F8 and PFO were done, and PFO was removed in 10-14 days. The patients were followed up for one year. The primary outcome was to achieve successful retinal reattachment, and the secondary outcomes were visual improvement and occurrence of complications.
Successful retinal reattachment was obtained in 28 eyes out of 30 (93.3%), and 2 eyes (6.7%) had recurrent RD. Best-corrected distance visual acuity (BCDVA) in logMAR was significantly improved from baseline 1.74 ± 0.05 to 0.93 ± 0.04, 0.82 ± 0.05, 0.80 ± 0.07, and 0.73 ± 0.055 at follow-up visits 3, 6, and 9 months and one year, respectively ( ≤ 0.001). There were no serious ocular complications recorded.
The results of this study indicated that primary vitrectomy with simultaneous use of both C3F8 and short-term PFO as retinal tamponades was effective and safe in the management of complex cases of RRD with PVR grade C and inferior breaks. This trial is registered with NCT04168255.
评估短期全氟正辛烷（PFO）与全氟丙烷（C3F8）气体联合使用，以实现伴有增殖性玻璃体视网膜病变（PVR）C级及包括下方裂孔在内的多个视网膜裂孔的孔源性视网膜脱离（RRD）患者视网膜复位的疗效和安全性。
这是一项前瞻性干预性病例系列研究。该研究为前瞻性非对照干预性研究。纳入了埃及米尼亚大学医院玻璃体视网膜科的30例RRD伴PVR C级及包括下方裂孔在内的多个视网膜裂孔患者的30只眼。平均年龄为50.2±10.63岁；女性18例，男性12例。行白内障超声乳化联合23G经平坦部玻璃体切除术（PPV），并用C3F8和PFO进行双重视网膜填塞，PFO在10 - 14天内取出。对患者进行了一年的随访。主要结局是实现视网膜成功复位，次要结局是视力改善和并发症的发生。
30只眼中有28只（93.3%）实现了视网膜成功复位，2只眼（6.7%）发生了复发性视网膜脱离。随访3个月、6个月、9个月和1年时，最佳矫正远视力（BCDVA）的logMAR值从基线时的1.74±0.05显著改善至0.93±0.04、0.82±0.05、0.80±0.07和0.73±0.055（P≤0.001）。未记录到严重的眼部并发症。
本研究结果表明，原发性玻璃体切除术联合使用C3F8和短期PFO作为视网膜填塞，在治疗伴有PVR C级和下方裂孔的RRD复杂病例中是有效且安全的。本试验已在ClinicalTrials.gov注册，注册号为NCT04168255。
